Narrator: The Purple Chair, take one…

Onscreen text: A POWERFUL PATIENT EDUCATION SERIES…

Donna: I used to ask…Why me? And then I developed the philosophy of why not me?

Onscreen text: FROM DIAGNOSIS…

Tami: All I heard was oncologist, and I got scared. I got really scared.

Mark: I automatically thought, “this is the cancer wing.”

Onscreen text: …TO FINDING A POSSIBLE PATH FORWARD.

Tami: I am going to find out what this thing I am fighting with is, and I'm going to find out a way to move forward…I was going to take charge again.

Onscreen text: SEE HOW THEY FOUND HOPE ON THEIR HEALTHCARE JOURNEYS…

Chuck: It was important for me to not just trust the doctor, but to also advocate for myself about what was going on in my body.

Onscreen text: AND HOW THEY FOUND ANSWERS THROUGH SELF-ADVOCACY.

Tami: I decided, "No, this is my life….I'm taking control. I'm going to find out what I need to know."

Chuck: Worry will kill you if you don't control it, so I control the worry…I investigate things. I ask questions, talk to the doctor.

Onscreen text: EXPLORE THE INSIGHTS, INSPIRATION, AND POSSIBILITIES SEATED WITHIN THEIR STORIES…

Tami: My diagnosis made me look at my life and actually start living it again.

Mark: I could really see the path forward in my journey.

Donna: I'm now on the path to possible.

Tami: If I can help someone else, if I can give them peace, if I can give them confidence, I mean, I'm 11 years in, and I'm still sassy, and I'm still loving life.

Onscreen text: THIS IS TAMI'S EXPERIENCE. YOURS MAY BE DIFFERENT.

Onscreen text: WATCH THE PURPLE CHAIR SERIES.

Donna: Purple is my favorite color…that color is just so optimistic.

Onscreen text: NOW PLAYING

BROUGHT TO YOU BY JAKAFI^® (ruxolitinib)

Onscreen text and narrator: Jakafi^® (ruxolitinib) is the first FDA-approved prescription medicine for adults with polycythemia vera (PV) who have already taken a medicine called hydroxyurea and it did not work well enough or they could not tolerate it. Jakafi is also the  first FDA-approved prescription medicine for adults with intermediate or high-risk myelofibrosis (MF).

Onscreen text and narrator: Important Safety Information 

Jakafi can cause serious side effects, including:

Low blood counts:  Jakafi^® (ruxolitinib) may cause low platelet, red blood cell, and white blood cell counts. If you develop bleeding, stop taking Jakafi and call your healthcare provider. Your healthcare provider will do a blood test to check your blood counts before you start Jakafi and regularly during your treatment. Your healthcare provider may change your dose of Jakafi or stop your treatment based on the results of your blood tests. Tell your healthcare provider right away if you develop or have worsening symptoms such as unusual bleeding, bruising, tiredness, shortness of breath, or a fever.

Infection:  You may be at risk for developing a serious infection during treatment with Jakafi. Tell your healthcare provider if you develop any of the following symptoms of infection: chills, nausea, vomiting, aches, weakness, fever, painful skin rash or blisters.

Cancer:  Some people have had certain types of non-melanoma skin cancers during treatment with Jakafi. Your healthcare provider will regularly check your skin during your treatment with Jakafi. Tell your healthcare provider if you develop any new or changing skin lesions during treatment with Jakafi.

Increases in cholesterol:  You may have changes in your blood cholesterol levels during treatment with Jakafi. Your healthcare provider will do blood tests to check your cholesterol levels about every 8 to 12 weeks after you start taking Jakafi, and as needed.

Increased risk of major cardiovascular events such as heart attack, stroke or death in people who have cardiovascular risk factors and who are current or past smokers while using another JAK inhibitor to treat rheumatoid arthritis:  Get emergency help right away if you have any symptoms of a heart attack or stroke while taking Jakafi, including: discomfort in the center of your chest that lasts for more than a few minutes, or that goes away and comes back, severe tightness, pain, pressure, or heaviness in your chest, throat, neck, or jaw, pain or discomfort in your arms, back, neck, jaw, or stomach, shortness of breath with or without chest discomfort, breaking out in a cold sweat, nausea or vomiting, feeling lightheaded, weakness in one part or on one side of your body, slurred speech

Increased risk of blood clots:  Blood clots in the veins of your legs (deep vein thrombosis, DVT) or lungs (pulmonary embolism, PE) have happened in people taking another JAK inhibitor for rheumatoid arthritis and may be life-threatening. Tell your healthcare provider right away if you have any signs and symptoms of blood clots during treatment with Jakafi, including: swelling, pain, or tenderness in one or both legs, sudden, unexplained chest or upper back pain, shortness of breath or difficulty breathing

Possible increased risk of new (secondary) cancers: People who take another JAK inhibitor for rheumatoid arthritis have an increased risk of new (secondary) cancers, including lymphoma and other cancers. People who smoke or who smoked in the past have an added risk of new cancers.

The most common side effects of Jakafi include:  for certain types of myelofibrosis (MF) and polycythemia vera (PV) – low platelet or red blood cell counts, bruising, dizziness, headache, and diarrhea; for acute GVHD – low platelet counts, low red or white blood cell counts, infections, and swelling; and for chronic GVHD – low red blood cell or platelet counts and infections including viral infections.

These are not all the possible side effects of Jakafi. Ask your pharmacist or healthcare provider for more information. Call your doctor for medical advice about side effects.

Before taking Jakafi, tell your healthcare provider about:  all the medications, vitamins, and herbal supplements you are taking and all your medical conditions, including if you have an infection, have or had low white or red blood cell counts, have or had tuberculosis (TB) or have been in close contact with someone who has TB, had shingles (herpes zoster), have or had hepatitis B, have or had liver or kidney problems, are on dialysis, have high cholesterol or triglycerides, had cancer, are a current or past smoker, had a blood clot, heart attack, other heart problems or stroke, or have any other medical condition. Take Jakafi exactly as your healthcare provider tells you. Do not change your dose or stop taking Jakafi without first talking to your healthcare provider.

Women should not take Jakafi while pregnant or planning to become pregnant. Do not breastfeed during treatment with Jakafi and for 2 weeks after the final dose.

Please see the Full Prescribing Information at Jakafi.com, which includes a more complete discussion of the risks associated with Jakafi.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch,
or call 1-800-FDA-1088.

You may also report side effects to Incyte Medical Information at 1-855-463-3463.

Onscreen text: LEARN MORE ABOUT JAKAFI

© 2021 Incyte Corporation. MAT-JAK-03258  12/21